 Indias supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the countrys big drugmakers, Cipla Ltd. Remdesivir, made by U.S.-based Gilead Sciences Inc, has been in high demand globally, and a handful of companies including Cipla are authorised to make and sell generic versions in 127 developing nations. Ciplas launch of remdesivir in late June, along with subsequent launches by others, has helped ease supply bottlenecks in India, Ciplas Global Chief Financial Officer, Kedar Upadhye, told Reuters. 